Brokerages expect Nektar Therapeutics (NASDAQ:NKTR) to report ($0.35) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.40). Nektar Therapeutics reported earnings of ($0.28) per share during the same quarter last year, which indicates a negative year over year growth rate of 25%. The business is scheduled to report its next quarterly earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($0.75) per share for the current fiscal year, with EPS estimates ranging from ($0.81) to ($0.71). For the next fiscal year, analysts forecast that the business will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.58) to ($0.57). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. The firm had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business’s quarterly revenue was up 321.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.32) EPS.
In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $24.14, for a total transaction of $2,414,000.00. Following the sale, the senior vice president now owns 84,871 shares in the company, valued at approximately $2,048,785.94. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Stephen K. Doberstein sold 43,677 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $24.97, for a total transaction of $1,090,614.69. The disclosure for this sale can be found here. In the last three months, insiders sold 941,427 shares of company stock worth $24,663,626. 6.10% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP bought a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $23,924,000. GSA Capital Partners LLP bought a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $1,454,000. Neuberger Berman Group LLC bought a new stake in Nektar Therapeutics during the 3rd quarter worth approximately $5,398,000. California Public Employees Retirement System raised its stake in Nektar Therapeutics by 2.3% during the 3rd quarter. California Public Employees Retirement System now owns 195,200 shares of the biopharmaceutical company’s stock worth $4,685,000 after acquiring an additional 4,300 shares during the period. Finally, Granahan Investment Management Inc. MA raised its stake in Nektar Therapeutics by 5.4% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 483,800 shares of the biopharmaceutical company’s stock worth $11,611,000 after acquiring an additional 24,599 shares during the period. Institutional investors own 96.00% of the company’s stock.
Shares of Nektar Therapeutics (NKTR) opened at $53.34 on Monday. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $55.42.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/04/0-35-earnings-per-share-expected-for-nektar-therapeutics-nktr-this-quarter.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.